Brainose Technologies

Company Overview

Snapshot

Founded in January 2017 by Yossi Bornstein and Ofer Spottheim, Brainose Technologies operated with 1–10 employees. The company ceased operations in March 2019.

Business overview

Brainose Technologies specializes in developing a nose-to-brain delivery system for cannabis-derived therapeutics, targeting central nervous system (CNS) indications. The company focused on creating pharmaceutical-grade cannabinoid-based therapies, with an initial emphasis on pain management, aiming for FDA and CE approval in the U.S. and Europe. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology, Medical Cannabis, and Drug Delivery, Brainose sought to provide accessible, safe, and efficient medication delivery for patients benefiting from cannabis-derived treatments.

Company Intelligence Q&A

What is Brainose Technologies' primary focus?

Brainose Technologies focuses on developing a nose-to-brain delivery system for cannabis-derived therapeutics, primarily for central nervous system (CNS) indications.

When was Brainose Technologies founded?

Brainose Technologies was founded in January 2017.

Who are the founders of Brainose Technologies?

Brainose Technologies was co-founded by Yossi Bornstein and Ofer Spottheim.

What markets did Brainose Technologies target for its products?

Brainose Technologies aimed for FDA and CE approval in the U.S. and Europe for its pharmaceutical-grade cannabinoid-based therapies.

When did Brainose Technologies cease operations?

Brainose Technologies ceased to operate in March 2019.